Complete Conference Coverage Archive

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.

Durable Responses With Single-agent Ibrutinib in CLL/SLL

Durable Responses With Single-agent Ibrutinib in CLL/SLL

A study suggests that single-agent ibrutinib results in durable responses among patients with CLL or SLL.

Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis

Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis

Data suggest that most patients with MM taking immunomodulatory therapy are not receiving appropriate thromboprophylaxis.

Leflunomide May Effectively Treat CMV After Allogeneic-HSCT

Leflunomide May Effectively Treat CMV After Allogeneic-HSCT

The findings of this study suggest that leflunomide may be an effective treatment of CMV infection among patients who have received allo-HSCT.

Patient Burden Related to Off-Label Prescribing in Sarcoma

Patient Burden Related to Off-Label Prescribing in Sarcoma

Data suggest that off-label prescribing may increase the time to treatment receipt, but may lower costs for patients.

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.

Sentinel Lymph Node Mapping Cost-effective in Endometrial Carcinoma

Sentinel Lymph Node Mapping Cost-effective in Endometrial Carcinoma

Study data suggest that SLN mapping is more cost-effective and more efficacious than routine LND or selective LND.

Elderly Patients and Treatment Tolerance in Phase 1 Trials

Elderly Patients and Treatment Tolerance in Phase 1 Trials

Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.

Reduction Strategies Improve Surgical Site Infection Rate After Colon Surgery

Reduction Strategies Improve Surgical Site Infection Rate After Colon Surgery

The results of this study show that implementation of strategies to reduce SSI can improve SSI rates, despite risk factors for infection.

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.

Adjuvant Chemotherapy Without Radiation Effective in Stage IB-IIA Cervical Cancer

Adjuvant Chemotherapy Without Radiation Effective in Stage IB-IIA Cervical Cancer

Data suggest that adjuvant chemotherapy without radiation may be an effective option for patients with stage IB to IIA cervical cancer with risk factors.

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

Data indicate that the addition of WPR to chemotherapy may provide a survival benefit, though prospective studies are needed to confirm these findings.

Aggressive Endometrial Cancer Subtypes More Common in African American Population

Aggressive Endometrial Cancer Subtypes More Common in African American Population

Study results suggest that aggressive molecular subtypes of endometrial cancer are more common among the African American population.

Burnout and Productivity Loss Among Gynecologic Oncologists

Burnout and Productivity Loss Among Gynecologic Oncologists

Gynecologic oncologists are at a particularly high risk for burnout compared with other specialties, suggesting a need for burnout prevention and wellness programs.

Hospital Readmission Reduction Program May Unfairly Penalize Hospitals

Hospital Readmission Reduction Program May Unfairly Penalize Hospitals

The Hospital Readmission Reduction Program may unfairly penalize hospitals if 30-day readmission rates are the only metric for care quality.

Isolated Tumor Cells and Routine Adjuvant Chemotherapy in Endometrial Cancer

Isolated Tumor Cells and Routine Adjuvant Chemotherapy in Endometrial Cancer

Patients with endometrial cancer who have isolated tumor cells identified by sentinel lymph node mapping should not routinely receive adjuvant chemotherapy.

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.

Cervical Cancer: SLN Biopsy Associated With Fewer Complications

Cervical Cancer: SLN Biopsy Associated With Fewer Complications

Sentinel lymph node biopsy was associated with fewer surgical complications, less lymphedema, and better quality of life.

Explaining Androgen Receptor-indifferent Prostate Cancer

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.

Urothelial Carcinoma: Year in Review

Urothelial Carcinoma: Year in Review

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.

Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible

Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible

A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.

Novel Mutated Genes, Pathways in Prostate Cancer Identified

Novel Mutated Genes, Pathways in Prostate Cancer Identified

Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.

Decipher Genomic Classifier Prognostic for Metastasis, PCa-specific Mortality

Decipher Genomic Classifier Prognostic for Metastasis, PCa-specific Mortality

The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Highest Genetic Risk Group Has 5-fold Higher Risk of Prostate Cancer

Highest Genetic Risk Group Has 5-fold Higher Risk of Prostate Cancer

The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.

Clinicians Address Barriers to Progress for Bladder Cancer

Clinicians Address Barriers to Progress for Bladder Cancer

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.

Impact of Early Immunotherapy Discontinuation in mRCC

Impact of Early Immunotherapy Discontinuation in mRCC

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

Targeting AR Mutations Promising In Prostate Cancer

Targeting AR Mutations Promising In Prostate Cancer

A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.

Nearly Half of Partners of Young Breast Cancer Survivors Report Anxiety

Nearly Half of Partners of Young Breast Cancer Survivors Report Anxiety

About 4 in 10 partners of young breast cancer survivors experience anxiety.

Exercise Reduction After Cancer Diagnosis: Factors and Consequences

Exercise Reduction After Cancer Diagnosis: Factors and Consequences

Three-quarters of patients diagnosed with cancer report decreased physical activity.

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.

Regorafenib Improves Overall Survival in Liver Cancer

Regorafenib Improves Overall Survival in Liver Cancer

Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.

PET Scans Inform, Improve Treatment in Esophageal Cancer

PET Scans Inform, Improve Treatment in Esophageal Cancer

Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.

Watch-and-Wait Safe for Patients With Rectal Cancer

Watch-and-Wait Safe for Patients With Rectal Cancer

Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.

Surgical Palliation for Gastric Outlet Obstruction

Surgical Palliation for Gastric Outlet Obstruction

Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.

Nintedanib Improves PFS in mCRC Regardless of Prior Regorafenib Treatment

Nintedanib Improves PFS in mCRC Regardless of Prior Regorafenib Treatment

Treatment with nintedanib significantly improved progression-free survival among heavily pretreated patients with metastatic colorectal cancer (mCRC).

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Findings from a preclinical study of PI3K inhibitor taselisib's mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

Cancer drug prices will probably continue their steady climb.

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.

Exercise and Gene Expression in Breast Cancer

Exercise and Gene Expression in Breast Cancer

Physical exercise might modulate the upregulation of immune and inflammatory-pathways involved in breast cancer.

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.

Ki67 Suppression With Abemaciclib in Breast Cancer

Ki67 Suppression With Abemaciclib in Breast Cancer

Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).

A Glimpse of ASH

A Glimpse of ASH

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.

Complications of Post-mastectomy Irradiation

Complications of Post-mastectomy Irradiation

Post-mastectomy radiotherapy is associated with increased rates of complications like hematoma, infection, and reduced patient-reported satisfaction.

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

Circulating tumor cell (CTC) counts prior to neoadjuvant chemotherapy for early-stage breast cancer predict survival.

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

Pathologic complete response (pCR) rates in hormone receptor (HR)-positive, HER2-positive breast cancer were unchanged.

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

BRCA1/2 mutation status does not predict survival among young patients.

Plasma Tumor DNA in Breast Oncology

Plasma Tumor DNA in Breast Oncology

Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).

Can Studying Tumor Ecology Reveal New Paths to Treatment?

Can Studying Tumor Ecology Reveal New Paths to Treatment?

Emerging research suggests that tumor development involves much more than mutant clones.

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.

The Challenges of Treating Triple-negative Breast Cancer

The Challenges of Treating Triple-negative Breast Cancer

A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.

No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years

No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years

Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.

Promising Options Emerging for Treating Metastatic ER+ Breast Cancer

Promising Options Emerging for Treating Metastatic ER+ Breast Cancer

Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.

Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer

Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer

Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.

Tumor, Node, and Metastasis Classification: 8th Edition Changes

Tumor, Node, and Metastasis Classification: 8th Edition Changes

The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters